23rd International AIDS Conference: Virtual

July 6-10, 2020; Virtual
CCO is the official provider of online scientific analysis for the 2020 International AIDS Conference through Capsule Summaries, downloadable slides, rapid expert Webinars, and ClinicalThought commentaries.

Highlights

Capsule Summary Slidesets

Among 5 patients with protocol-defined virologic failure at Week 48 in this study, none experienced HIV-1 RNA > 200 copies/mL.

Released: July 5, 2020

Switching to 2-drug ART did not increase risk of virologic suppression, serious non-AIDS events, or death in virologically suppressed persons with HIV.

Released: July 10, 2020

Analysis of data from 4 international trials of switching to BIC/FTC/TAF found high rate of efficacy and favorable tolerability in older virologically suppressed patients.

Released: July 11, 2020

During the first 9 months following a switch from TDF- to TAF-based ART, estimated annual rates of weight gain ranged from 1.80-4.47 kg across regimens. These gains subsequently slowed or plateaued but occurred regardless of concomitant INSTI use.

Released: July 10, 2020

More than 2 years after the switch to DOR/3TC/TDF, adjusted mean weight gains ranged from 1.2-1.4 kg with no evident differences by sex, race, or ethnicity. The majority of patients (~ 70%) experienced < 5% weight gain at Week 144 of the study.

Released: July 10, 2020

Lipid and fasting insulin changes favored the switch to 2 drugs with a lower risk of insulin resistance compared with continued 3-drug or 4-drug TAF-based regimens in this international study of virologically suppressed adults.

Released: July 11, 2020

Noninferiority of first-line DTG-based vs EFV-based regimens maintained through Week 96, with significantly greater weight gain observed in PWH receiving DTG + FTC/TAF.

Released: July 10, 2020

Long-acting CAB injected intramuscularly every 2 months reduced the risk of HIV infection by 66% compared with daily oral TDF/FTC in high-risk MSM and transgender women.

Released: July 11, 2020

In an updated analysis of data through April 2020, NTD prevalence among infants of women who received DTG at conception continues to be slightly higher than among those without HIV or who received non-DTG ART.

Released: July 11, 2020

Results demonstrate that this novel investigational first-in-class HIV-1 capsid inhibitor was generally well tolerated after single-dose administration in healthy volunteers, with PK supportive of a 6-month dosing interval.

Released: July 10, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?